Aciont
Envisioning the Future of Ocular Therapeutics
About Us | Unmet Needs | Technologies | Product Pipeline | Media & Investors
About Us

Ophthalmic Advisors

Paul Bernstein, M.D., Ph.D.
Dr. Bernstein is a tenured Associate Professor of Ophthalmology and Visual Sciences at the Moran Eye Center at the University of Utah School of Medicine. Paul received his M.D. and Ph.D. in Pharmacology from Harvard Medical School and graduated Summa Cum Laude. His residency was in retinal cell biology was at Jules Stein Eye Institute of UCLA School of Medicine, where he was awarded the prestigious Jules Stein Resident Research Award. Paul did his fellowship in vitreoretinal surgery and research at Massachusetts Eye & Ear Infirmary of Harvard Medical School.
Richard E. Dobbs, Ph.D.
Dr. Dobbs brings over 35 years of medical research experience and has over 25 year in the field of clinical research and drug development, the majority of which is in the area of ophthalmology. Dr. Dobbs has worked in both the pharmaceutical company and contract research environments and has extensive experience in managing global clinical trials and drug development programs as well as leading global operations organizations. Dr. Dobbs’ experience in the clinical research industry includes strategic clinical development planning, including regulatory strategies, monitoring and managing of clinical project teams from IND to NDA and in-licensing and due diligence of new molecules.
Albert Vitale, M.D.
Dr. Vitale is one of the only ophthalmologists in the Intermountain West specializing in the diagnosis, medical treatment and surgical treatment of the retina, uveitis, other ocular infections and inflammatory diseases of the eye. His research interest includes ocular manifestations of systemic diseases, novel therapeutic agents, new drug delivery systems in the treatment of his specialties. He is an Associate Professor of Ophthalmology & Visual Sciences at the University of Utah’s Moran Eye Center. Albert went to medical school at New York Medical College, his Residency at St. Vincent’s Hospital & Medical Center in NYC and his Fellowship at Harvard University.
Nick Mamalis, M.D
Dr. Mamalis is a Professor of Ophthalmology, Director of Ophthalmic Pathology, and Director of the Intermountain Ocular Research Center at the Moran Eye Center at the University of Utah School of Medicine. Nick did his undergraduate training at Harvard University and completed Medical School and a fellowship in Ophthalmic Pathology at University of Utah. His residency was done at Loyola University Medical Center. Dr. Mamalis' research expertise is utilized by many Ophthalmic companies seeking his opinion in the areas of intraocular lenses and postoperative inflammation.
David J. Miller, Ph.D.
David Miller has over 10 years experience with iontophoretic systems, including 5 years of research and development work on commercial iontophoretic systems. He headed interdisciplinary teams focused on transdermal iontophoretic drug delivery, and has headed an international, interdisciplinary team focused on ocular iontophoretic drug delivery. He is an inventor on several patents and has authored many papers on the related subjects. Miller received a B.S. in Pharmacy from Ferris State University, a M.S. in Pharmaceutics from the University of Michigan and a Ph.D. in Pharmaceutics from the University of Michigan.
S. Kevin Li, Ph.D.
Dr. Li is an Associate Professor at the University of Cincinnati in the Department of Pharmacy. Prior to that he was a Research Associate Professor in the Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah. He graduated Summa Cum Laude from Brigham Young University where he earned his BA in Chemistry. Dr. Li earned his Ph.D. in Pharmaceutics and Pharmaceutical Chemistry from the University of Utah. Dr. Li has published more than 25 articles ranging from permeation enhancers to alternating current iontophoresis. Dr. Li has advanced research in transdermal drug delivery, and more recently, is focusing his talents and research on transscleral drug delivery.
J. Michael Delmage, Ph.D., MBA.
Dr. Delmage is a pharmaceutical/biotechnology expert with more than 25 years experience in companies involved in the research, development and commercialization of leading biotechnology products, medical devices and therapeutics. Most recently he was corporate co-founder of LINC Pharmaceuticals, a company leading in the area of anti-fibrotic technologies. He also co-founded Oculex, which was later purchased by Allergan in 2003 for their ophthalmic drug delivery expertise. Mike was also a Director of Santen OY and the Senior Vice President of Research and Development at Santen International and led the approval and commercialization activities for Santen's U.S. and European products. Dr. Delmage holds a Ph.D. in Cellular and Molecular Biology from the University of Southern California, and an MBA from Pepperdine University.